| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Departments of Urology, Kimmel Cancer Center,*
Pathology and Cell Biology,
and Microbiology
and Immunology,
Jefferson Medical College of
Thomas Jefferson University, Philadelphia, Pennsylvania; and the
Department of Urology,§
University of Padova,
Padua, Italy
Cytogenetic and loss of heterozygosity (LOH) studies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC). We recently cloned the tumor suppressor gene FHIT (fragile histidine triad) at 3p14.2, one of the most frequently deleted chromosomal regions in TCC of the bladder, and showed that it is the target of environmental carcinogens. Abnormalities at the FHIT locus have been found in tumors of the lung, breast, cervix, head and neck, stomach, pancreas, and clear cell carcinoma of the kidney. We examined six TCC derived cell lines (SW780, T24, Hs228T, CRL7930, CRL7833, and HTB9) and 30 primary TCC of the bladder for the integrity of the FHIT transcript, using reverse transcriptase–polymerase chain reaction (RT-PCR) to investigate a potential role of the FHIT gene in TCC of the bladder. In addition, we tested expression of the Fhit protein in the six TCC-derived cell lines by Western blot analysis and in 85 specimens of primary TCCs by immunohistochemistry. Three of the six cell lines (50%) did not show the wild-type FHIT transcript, and Fhit protein was not detected in four of the six cell lines (67%) tested. Fhit expression also was correlated with pathological and clinical status. A significant correlation was observed between reduced Fhit expression and advanced stage of the tumors. Overall, 26 of 30 (87%) primary TCCs showed abnormal transcripts. Fhit protein was absent or greatly reduced in 61% of the TCCs analyzed by immunohistochemistry. These results suggested that loss of Fhit expression may be as important in the development of bladder cancer as it is for other neoplasms caused by environmental carcinogens.
This article has been cited by other articles:
 |
|
 |
|
  P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vecchione, C. Sevignani, E. Giarnieri, N. Zanesi, H. Ishii, R. Cesari, L. Y. Y. Fong, L. G. Gomella, C. M. Croce, and R. Baffa Inactivation of the FHIT Gene Favors Bladder Cancer Development Clin. Cancer Res., November 15, 2004; 10(22): 7607 - 7612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, A. Vecchione, Y. Furukawa, K. Sutheesophon, S.-Y. Han, T. Druck, T. Kuroki, F. Trapasso, M. Nishimura, Y. Saito, et al. Expression of FRA16D/WWOX and FRA3B/FHIT Genes in Hematopoietic Malignancies Mol. Cancer Res., November 1, 2003; 1(13): 940 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mascaux, B. Martin, J.M. Verdebout, A.P. Meert, V. Ninane, and J.P. Sculier Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 Eur. Respir. J., May 1, 2003; 21(5): 753 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines PNAS, March 19, 2002; 99(6): 3615 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Maruyama, S. Toyooka, K. O. Toyooka, K. Harada, A. K. Virmani, S. Zochbauer-Muller, A. J. Farinas, F. Vakar-Lopez, J. D. Minna, A. Sagalowsky, et al. Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features Cancer Res., December 1, 2001; 61(24): 8659 - 8663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-G. Lee, H.-Y. Kim, D.-S. Byun, S.-J. Lee, C.-H. Lee, J. I. Kim, S.-G. Chang, and S.-G. Chi Frequent Epigenetic Inactivation of RASSF1A in Human Bladder Carcinoma Cancer Res., September 1, 2001; 61(18): 6688 - 6692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vecchione, N. Zanesi, G. Trombetta, D. French, P. Visca, T. Pisani, C. Botti, A. Vecchione, C. M. Croce, and R. Mancini Cervical Dysplasia, Ploidy, and Human Papillomavirus Status Correlate with Loss of Fhit Expression Clin. Cancer Res., May 1, 2001; 7(5): 1306 - 1312. [Abstract] [Full Text]
|
|
|
|
|
|
T. Shiraishi, T. Druck, K. Mimori, J. Flomenberg, L. Berk, H. Alder, W. Miller, K. Huebner, and C. M. Croce Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit PNAS, April 18, 2001; (2001) 91095898. [Abstract] [Full Text]
|
|
|
|
|
|
J. I. Lee, J.-C. Soria, K. Hassan, D. Liu, X. Tang, A. El-Naggar, W. K. Hong, and L. Mao Loss of Fhit Expression Is a Predictor of Poor Outcome in Tongue Cancer Cancer Res., February 1, 2001; 61(3): 837 - 841. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ishii, K. R. Dumon, A. Vecchione, F. Trapasso, K. Mimori, H. Alder, M. Mori, G. Sozzi, R. Baffa, K. Huebner, et al. Effect of Adenoviral Transduction of the Fragile Histidine Triad Gene into Esophageal Cancer Cells Cancer Res., February 1, 2001; 61(4): 1578 - 1584. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Borzacchiello, V. Ambrosio, P. Galati, F. Poggiali, A. Venuti, and F. Roperto The Pagetoid Variant of Urothelial Carcinoma In Situ of Urinary Bladder in a Cow Vet. Pathol., January 1, 2001; 38(1): 113 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mori, K. Mimori, T. Shiraishi, H. Alder, H. Inoue, Y. Tanaka, K. Sugimachi, K. Huebner, and C. M. Croce Altered Expression of Fhit in Carcinoma and Precarcinomatous Lesions of the Esophagus Cancer Res., March 1, 2000; 60(5): 1177 - 1182. [Abstract] [Full Text]
|
|
|
|
|
|
T. Shiraishi, T. Druck, K. Mimori, J. Flomenberg, L. Berk, H. Alder, W. Miller, K. Huebner, and C. M. Croce Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit PNAS, May 8, 2001; 98(10): 5722 - 5727. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
